KRAS and thyroid gland undifferentiated (anaplastic) carcinoma: Taken together, the results depicted here support the suggestion that K-Ras and Gal-3 inhibition should be considered as a novel therapeutic treatment for patients suffering from anaplastic thyroid carcinoma.